Cipla’s subsidiary to acquire US-based Avenue Therapeutics for USD 215 mn

Drug major Cipla Tuesday said its subsidiary InvaGen Pharmaceuticals Inc has entered into definitive agreements to acquire US-based speciality business firm Avenue Therapeutics for up to USD 215 million (around Rs 1,560 crore).

from The Financial ExpressThe Financial Express https://ift.tt/2FgXrrq
via IFTTT